Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Foghorn Therapeutics Inc.
Report date June 21, 2024 · Filed June 24, 2024
Section 16 reporting ended · disclosed 2024-06-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 86,992 |
Reported balance
Holding disclosure · report date 2024-06-21 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 86,992 |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2028-03-27 | Direct | 5,575 |
Reported balance
Holding disclosure · report date 2024-06-21 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 5,575 F1: The option vested as to 25% of the underlying shares of common stock on March 19, 2019, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.72 · Expires 2029-02-12 | Direct | 10,135 |
Reported balance
Holding disclosure · report date 2024-06-21 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 10,135 F2: The option vested as to 25% of the underlying shares of common stock on January 30, 2020, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.77 · Expires 2030-08-17 | Direct | 59,459 |
Reported balance
Holding disclosure · report date 2024-06-21 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 59,459 F3: The option vested as to 25% of the underlying shares of common stock on August 18, 2021, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.63 · Expires 2031-01-27 | Direct | 50,000 |
Reported balance
Holding disclosure · report date 2024-06-21 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 50,000 F4: The option vested as to 25% of the underlying shares of common stock on January 28, 2022, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.87 · Expires 2032-01-25 | Direct | 125,000 |
Reported balance
Holding disclosure · report date 2024-06-21 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 125,000 F5: The option vested as to 25% of the underlying shares of common stock on January 26, 2023, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.38 · Expires 2033-01-25 | Direct | 65,000 |
Reported balance
Holding disclosure · report date 2024-06-21 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 65,000 F6: The option vested as to 25% of the underlying shares of common stock on January 26, 2024, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.06 · Expires 2034-01-23 | Direct | 80,000 |
Reported balance
Holding disclosure · report date 2024-06-21 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 80,000 F7: The option vests as to 25% of the underlying shares of common stock on January 24, 2025, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vested as to 25% of the underlying shares of common stock on March 19, 2019, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
F2: The option vested as to 25% of the underlying shares of common stock on January 30, 2020, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
F3: The option vested as to 25% of the underlying shares of common stock on August 18, 2021, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
F4: The option vested as to 25% of the underlying shares of common stock on January 28, 2022, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
F5: The option vested as to 25% of the underlying shares of common stock on January 26, 2023, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
F6: The option vested as to 25% of the underlying shares of common stock on January 26, 2024, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
F7: The option vests as to 25% of the underlying shares of common stock on January 24, 2025, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 11, 2024 Filed Mar 12, 2024 20:19 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | SaleCommon Stock | 11,000 | $6.56 | $72,133.60 |
DisclosureSEC source: 0001562180-24-002591 · primarydocument.xml · nonDerivative · entry 1 Cavalie Fanny · CIK 0001913484 · Chief Strategy/Bus Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,992 F1 · price: This transaction was executed in multiple trades at prices ranging from $6.50 USD to $6.83 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| January 24, 2024 Filed Jan 25, 2024 21:03 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 80,000 | $3.06 Strike: $3.06 | $244,800.00 |
DisclosureSEC source: 0001562180-24-000608 · primarydocument.xml · derivative · entry 1 Cavalie Fanny · CIK 0001913484 · Chief Strategy/Bus Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2034-01-23 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares of common stock on January 24, 2025, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 22:04 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $8.38 | $0.00 |
DisclosureSEC source: 0001562180-23-000727 · primarydocument.xml · derivative · entry 1 Cavalie Fanny · CIK 0001913484 · Chief Strategy/Bus Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2033-01-25 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares of common stock on January 26, 2024, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.